Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2011, Article ID 984340, 7 pages
http://dx.doi.org/10.1155/2011/984340
Clinical Study

Sequential Dose-Dense Doxorubicin and Ifosfamide in Advanced Soft-Tissue Sarcoma Patients in an Out-Patient-Basis Schedule

1Servico de Oncologia Clinica, Instituto de Radiologia, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, 05403-900 Sao Paulo, SP, Brazil
2Centro de Hematologia e Oncologia—CEHON, Avenida Araujo Pinho, 439 Canela, 40110-150 Salvador, BA, Brazil
3Servico de Anatomia Patologica, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, 05403-010 Sao Paulo, SP, Brazil
4Terceira Clinica Cirurgica, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, 05403-010 Sao Paulo, SP, Brazil
5Instituto de Ortopedia e Traumatologia, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, 05403-010 Sao Paulo, SP, Brazil
6Laboratorio de Anatomia Patologica, Instituto de Ortopedia e Traumatologia, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, 05403-010 Sao Paulo, SP, Brazil

Received 8 August 2010; Revised 5 April 2011; Accepted 4 May 2011

Academic Editor: R. Pollock

Copyright © 2011 G. F. G. Almeida et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. V. H. Bramwell, D. Anderson, and M. L. Charette, “Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma,” The Cochrane Database of Systematic Reviews, no. 3, Article ID CD003293, 2003. View at Google Scholar
  2. B. Yalcin, A. Pamir, A. Buyukcelik et al., “High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas,” Experimental Oncology, vol. 26, no. 4, pp. 320–325, 2004. View at Google Scholar · View at Scopus
  3. J. Maurel, J. Fra, A. López-Pousa et al., “Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a phase II trial by the spanish group for research on sarcomas (GEIS),” Cancer, vol. 100, no. 7, pp. 1498–1506, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Maurel, A. López-Pousa, R. De Las Peñas et al., “Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas,” Journal of Clinical Oncology, vol. 27, no. 11, pp. 1893–1898, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. N. Pervaiz, N. Colterjohn, F. Farrokhyar, R. Tozer, A. Figueredo, and M. Ghert, “A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma,” Cancer, vol. 113, no. 3, pp. 573–581, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. W. H. Weng, J. Ahlén, K. Aström, W. O. Lui, and C. Larsson, “Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas,” Clinical Cancer Research, vol. 11, no. 17, pp. 6198–6204, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. K. W. Hunter, “Ezrin, a key component in tumor metastasis,” Trends in Molecular Medicine, vol. 10, no. 5, pp. 201–204, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. T. A. Martin, G. Harrison, R. E. Mansel, and W. G. Jiang, “The role of the CD44/ezrin complex in cancer metastasis,” Critical Reviews in Oncology/Hematology, vol. 46, no. 2, pp. 165–186, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Gautreau, P. Poullet, D. Louvard, and M. Arpin, “Ezrin, a plasma membrane-microfilament linker, signals cell survival through the phosphatidylinositol 3-kinase/akt pathway,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 13, pp. 7300–7305, 1999. View at Publisher · View at Google Scholar · View at Scopus
  10. Y. Yu, J. Khan, C. Khanna, L. Helman, P. S. Meltzer, and G. Merlino, “Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein six-1 as key metastatic regulators,” Nature Medicine, vol. 10, no. 2, pp. 175–181, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Khanna, X. Wan, S. Bose et al., “The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis,” Nature Medicine, vol. 10, no. 2, pp. 182–186, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Therasse, S. G. Arbuck, and E. A. Eisenhauer, “New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the united states, national cancer institute of canada,” Journal of the National Cancer Institute, vol. 92, no. 3, pp. 205–216, 2000. View at Google Scholar
  13. R. Simon, “Optimal two-stage designs for phase II clinical trials,” Controlled Clinical Trials, vol. 10, no. 1, pp. 1–10, 1989. View at Google Scholar · View at Scopus
  14. S. Leyvraz, R. Herrmann, L. Guillou et al., “Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies,” British Journal of Cancer, vol. 95, no. 10, pp. 1342–1347, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Morales-Arias, P. A. Meyers, M. F. Bolontrade et al., “Expression of granulocyte-colony-stimulating factor and its receptor in human Ewing sarcoma cells and patient tumor specimens: potential consequences of granulocyte-colony-stimulating factor administration,” Cancer, vol. 110, no. 7, pp. 1568–1577, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. C. C. Kirwan, G. McDowell, C. N. McCollum, S. Kumar, and G. J. Byrne, “Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer,” British Journal of Cancer, vol. 99, no. 7, pp. 1000–1006, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. G. Sutton, V. L. Brunetto, L. Kilgore et al., “A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a gynecologic oncology group study,” Gynecologic Oncology, vol. 79, no. 2, pp. 147–153, 2000. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Ferrari, M. Casanova, G. Bisogno et al., “Clear cell sarcoma of tendons and aponeuroses in pediatric patients: a report from the Italian and German Soft Tissue Sarcoma Cooperative Group,” Cancer, vol. 94, no. 12, pp. 3269–3276, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Saintigny, B. Besse, P. Callard et al., “Erythropoietin and erythropoietin receptor coexpression is associated with poor survival in stage I non-small cell lung cancer,” Clinical Cancer Research, vol. 13, no. 16, pp. 4825–4831, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Le Cesne, E. Antoine, M. Spielmann et al., “High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas,” Journal of Clinical Oncology, vol. 13, no. 7, pp. 1600–1608, 1995. View at Google Scholar · View at Scopus
  21. G. Rosen, C. Forscher, S. Lowenbraun et al., “Synovial sarcoma: uniform response of metastases to high dose ifosfamide,” Cancer, vol. 73, no. 10, pp. 2506–2511, 1994. View at Publisher · View at Google Scholar · View at Scopus
  22. T. O. Nielsen, R. B. West, S. C. Linn et al., “Molecular characterisation of soft tissue tumours: a gene expression study,” Lancet, vol. 359, no. 9314, pp. 1301–1307, 2002. View at Google Scholar
  23. P. Francis, H. M. Namløs, C. Müller et al., “Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential,” BMC Genomics, vol. 8, pp. 73–88, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. C. Seidel, F. Bartel, M. Rastetter et al., “Alterations of cancer-related genes in soft tissue sarcomas: hypermethylation of RASSF1A is frequently detected in leiomyosarcoma and associated with poor prognosis in sarcoma,” International Journal of Cancer, vol. 114, no. 3, pp. 442–447, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. A. H. Beck, C Lee, and D. M. Witten, “Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling,” Oncogene, vol. 29, no. 6, pp. 845–854, 2010. View at Google Scholar
  26. J. Barretina, B. S. Taylor, S. Banerji et al., “Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy,” Nature Genetics, vol. 42, pp. 715–721, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Moilanen, H. Lassus, A. Leminen, A. Vaheri, R. Bützow, and O. Carpén, “Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients,” Gynecologic Oncology, vol. 90, no. 2, pp. 273–281, 2003. View at Publisher · View at Google Scholar · View at Scopus